Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma
Abstract
Coronavirus disease 2019 (COVID-19) has swept the globe and poses unique treatment challenges for immunocompromised patients with hematologic malignancies. Here, we present the case of a 54-year-old man with follicular lymphoma, recently completing treatment with maintenance rituximab, who endured a protracted course of COVID-19. The patients case was complicated by evolving hypoxic respiratory failure, marked lymphopenia, and hypogammaglobulinemia, which ultimately led to treatment with COVID-19 convalescent plasma, resulting in clinical improvement. Presently, there is no definitive data on the efficacy ofCOVID-19 convalescent plasma in patients withCOVID-19; however, many trials are ongoing. We propose that this may be an effective treatment inpatients treated for lymphoma with subsequent lymphopenia and hypogammaglobulinemia.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 19, 2020
- Accession Number
- AD1105950
Entities
People
- Adrian Bersabe
- Andrew P Cap
- Rina Eden
- Zachary Wright